Denosumab, a RANK ligand inhibitor, for postmenopausal women with osteoporosis.

Denosumab, a RANK ligand inhibitor, for postmenopausal women with osteoporosis.

Item
http://www.wikidata.org/entity/Q38029995
A practical approach to osteoporosis management in the geriatric populationA Bone Anabolic Effect of RANKL in a Murine Model of Osteoporosis Mediated Through FoxP3+ CD8 T Cells.Interplay between CaSR and PTH1R signaling in skeletal development and osteoanabolism.The innovative medicines initiative: a public private partnership model to foster drug discovery.Osteoporosis in older persons: current pharmacotherapy and future directions.The inhibition of RANK-ligand in the management of postmenopausal osteoporosis and related fractures: the role of denosumab.Antiosteoclastic activity of milk thistle extract after ovariectomy to suppress estrogen deficiency-induced osteoporosis.The Potential of microRNAs for Stem Cell-based Therapy for Degenerative Skeletal Diseases.Seropharmacological study on osteogenic effects of post-absorption ingredients of an osteoprotective herbal formula.
P2860

Denosumab, a RANK ligand inhibitor, for postmenopausal women with osteoporosis.

Item
http://www.wikidata.org/entity/Q38029995
description
article científic
@ca
article scientifique
@fr
articol științific
@ro
articolo scientifico
@it
artigo científico
@gl
artigo científico
@pt
artigo científico
@pt-br
artikel ilmiah
@id
artikull shkencor
@sq
artículo científico
@es
name
Denosumab, a RANK ligand inhibitor, for postmenopausal women with osteoporosis.
@en
type
label
Denosumab, a RANK ligand inhibitor, for postmenopausal women with osteoporosis.
@en
prefLabel
Denosumab, a RANK ligand inhibitor, for postmenopausal women with osteoporosis.
@en
P1433
P1476
P2093
P2860
P304
P31
P356
P407
P433
P478
P577
P698
P921
P356
P1433
P1476
Denosumab, a RANK ligand inhibitor, for postmenopausal women with osteoporosis.
@en
P2093
P2860
P304
P31
P356
P407
P433
P478
P577
P698
P921